There is one clinical trial.
This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.
Description: COVID-19 serology testingMeasure: Virology Cure Rate Time: 10 days
Description: Measure incidence of diarrhea, vomiting, nausea and constipationMeasure: Incidence of GI adverse events Time: 47 days
Description: 12-Lead ECG daily if QTc >500 msecMeasure: Cardiac Toxicity Time: 10 days
Description: Measure blood countsMeasure: Changes in WBC w Diff, B cells, T cells, NK cells Time: 10 days
Description: Measure changes in plasma cytokines throughout course of infectionMeasure: Changes in cytokine levels, IL-1, IL-6, IL-12, IL-18, TNF-a Time: 10 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports